MoneyShow, Contributor

In spite of Covid-19 and global recession concerns, we have a positive outlook on the biotechnology sub-industry; we expect to see a ramp-up in new drug sales; the continued development of many new, innovative therapies; and a decline in the prevalence…

Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology space.

Drug stocks have been out of favor due to regulatory concerns. Nevertheless, several top-tier stock experts and contributors to MoneyShow.com see select opportunities for long-term value investors to consider buying large cap pharmaceutical names.

The following seven dividend stocks have strong business models, durable competitive advantages, and high dividend yields above 5% that make them extremely attractive stocks for retirees, says Ben Reynolds, a contributor to MoneyShow.com, an income exp…

Kelley Wright is a dividend specialist, a contributor to MoneyShow.com and the editor of the industry-leading advisory service Investment Quality Trends. His Timely Ten list represents his top ten current recommendations chosen from among his universe …

Dividend Aristocrats are an elite group of 57 stocks that are in the S&P 500 , meet certain minimum size and liquidity requirements and have 25+ years of consecutive dividend increases, explains Ben Reynolds, editor of Sure Dividend.